Article
Pfizer, MediVas team for ophthalmic drug delivery
New York-Pfizer Inc. and MediVas LLC have inked a collaborative agreement to research and develop advanced delivery methods for Pfizer compounds treating ophthalmic diseases.
New York-Pfizer Inc. and MediVas LLC have inked a collaborative agreement to research and develop advanced delivery methods for Pfizer compounds treating ophthalmic diseases.
The deal centers on MediVas' fully biodegradable and biocompatible polymers in combination with Pfizer's ophthalmic compounds to increase therapy adherence and improve eye treatments.
MediVas is based in San Diego. Financial terms were not disclosed.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
